Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics has appointed Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is a seasoned drug developer and physician with a history of building and leading companies focused on various therapeutic areas, including rare diseases. His addition to the Board will support the company as it progresses its pipeline of programmable recombinase products toward clinical trials.
Adam Rosenberg, Independent Chairman of the Board of Seamless Therapeutics, stated that Alvin’s proven ability to help biotech companies advance their therapeutic and corporate development will be invaluable in supporting the company’s growth and its discovery pipeline. He added that Dr. Shih’s clinical expertise and business insight will strengthen Seamless’ ability to leverage its potentially transformative platform to achieve advancements in genetic medicine.
Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics, said that the company’s goal is to become a global leader in next-generation gene editing therapeutics to address the significant unmet needs of patients with inherited diseases. He believes that Alvin’s extensive knowledge in developing first-in-class treatments will provide important strategic perspectives to the company’s development and commercial strategies. With upcoming *in vivo* data further validating the potential of their precision gene editing approach, he looks forward to collaborating with the experienced Board members to fully realize the potential of their groundbreaking technologies.
Dr. Shih is a biotech leader with a focus on rare diseases and has overseen the development of multiple approved therapies in this area. He currently serves as the CEO of Imbria Pharmaceuticals, a clinical-stage biotech company focused on developing new therapies for patients with cardiometabolic disorders. Previously, he was the President and CEO of Catamaran Bio and, before that, the CEO of Disarm Therapeutics, a private neuroscience company acquired by Eli Lilly in 2020 under his leadership. Prior to that, he was the CEO of Enzyvant Therapeutics, a biotechnology company focused on regenerative medicines for rare diseases. Earlier in his career, he held the position of head of R&D at Retrophin and Chief Operating Officer of the Pfizer Rare Disease Research Unit. Dr. Shih began his career as a strategy consultant at McKinsey & Co. and L.E.K. Consulting. He holds an M.D. from the University of Alabama Medical School and an M.B.A. from the Northwestern University Kellogg School of Management. Dr. Shih is a Director on the Boards of several venture-backed, public and nonprofit life science companies, including Zevra Therapeutics and Tenza Bio.
***
About Seamless Therapeutics
Seamless Therapeutics is transforming gene editing through an innovative approach with the potential to address unmet medical needs in patients with severe conditions. Their technology platform allows for the programming of recombinases, a highly adaptable class of enzymes. They are using their proprietary expertise to develop a pipeline of disease-modifying product candidates across a wide range of indications to expand the therapeutic possibilities of gene editing.
For more information, please contact:
Seamless Therapeutics
Albert Seymour, CEO
Email:
Seamless Therapeutics media inquiries
Trophic Communications
Stephanie May and Eva Mulder
Tel: +49 171 1855682 or +31 6 52 33 15 79
Email:
Attachment
